On Tuesday, Novartis and GlaxoSmithKline announced a series of transactions worth more than $20 billion that fundamentally transforms Novartis by more tightly focusing the company’s product line without significantly reducing its revenue. The Novartis-Glaxo transactions potentially allow each company to build on their respective strengths, while removing smaller noncompetitive businesses. The deal with Glaxo, and a separate deal … Read more
After a stalemate lasting almost a year, Novartis and Alcon finally reached a buyout price for the remaining 23% of Alcon that has been in the hands of minority shareholders. The new offer of $168 per share consists of 2.8 shares of Novartis and a contingent value amount in cash to lock in the $168 … Read more
Novartis develops and manufactures health-care products within its four main operating segments: branded pharmaceuticals, generic pharmaceuticals, diagnostic and vaccines, and consumer products. The acquisition of Alcon brings an increased presence in the eye-care industry. The company was created by the merger of Sandoz AG and Ciba-Geigy AG in December 1996. The company went public on … Read more
A recent survey conducted by a UK-based consultancy found Johnson & Johnson ranked best for trustworthiness and Novartis best at handling relationships with patient groups. 2009 Study: HSC Issue 47 Both companies are important holdings in our portfolio; however, most clients are less familiar with Novartis than they are with Johnson & Johnson. Novartis develops … Read more
On Monday, January 4th, Novartis announced its desire to assume full control of Alcon (Ticker: ACL) through a two part process. First, it will exercise its call option with current majority owner, NestlГ© (Ticker: NSRGY). Novartis then plans to exchange new shares for the remaining 23% publicly-owned Alcon shares. Back in April 2008 Novartis purchased … Read more